Zoptrex licensing deals welcomed by Aeterna and Ergomed

2 September 2016

Canada’s Aeterna Zentaris (TSX: AEZ) has signed a second licensing deal in as many months over the anti-cancer compound Zoptrex (zoptarelin doxorubicin), it has announced along with its co-development partner, UK-based Ergomed (LSE: ERGO).

In early July, Aeterna Zentaris and Orient EuroPharma (OEP) announced the signing of an exclusive license agreement between the company and Cyntec, an affiliate of OEP, for Zoptrex, for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia.

Now the Quebec-based company has signed an exclusive Zoptrex license agreement for the same indication with privately-held RAFA Laboratories for Israel and the Palestine Territories.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK